Continuous Renal Replacement Therapy Market by Product, Modality, Age Group, Indication, End User

Description

List of Tables

[187 Pages Report] The Continuous Renal Replacement Therapy Market size was estimated at USD 14.28 billion in 2023 and expected to reach USD 15.49 billion in 2024, at a CAGR 8.55% to reach USD 25.37 billion by 2030.

Continuous renal replacement therapy (CRRT) is a specialized medical treatment utilized for continuous dialysis to allow solute and fluid homeostasis. CRRT provides continuous renal support by mimicking the natural function of the kidneys in removing waste products, excess fluids, and electrolytes from the blood while maintaining optimal acid-base balance. The CRRT is witnessing significant growth due to several factors, including the increasing prevalence of AKI incidences globally and rising technological advancements in extracorporeal dialysis and lithotripsy. In addition, significant advantages of CRRT in intermittent blood purification boost the market expansion. However, the high cost associated with the renal replacement procedure and concerns over potential complications during therapies subsequently hampers the growth of CRRT. Moreover, ongoing innovation and research activities, including developing novel membrane materials and advanced therapy options with improved biocompatibility and widening uses of CCRT systems for pediatric patients, contribute to the future CRRT.

KEY MARKET STATISTICS
Base Year [2023]	USD 14.28 billion
Estimated Year [2024]	USD 15.49 billion
Forecast Year [2030]	USD 25.37 billion
CAGR (%)	8.55%

Regional Insights

In the Americas, countries such as the United States and Canada hold a significant share of the CRRT market, with the major factors driving the growth, including the increasing prevalence of renal diseases and technological advancements and research & development activities by major companies. Additionally, in Europe, the presence of leading manufacturers, increased need for advanced therapies, and supportive government policies, such as European CE marking for renal therapy products, contribute to the expansion of the CRRT market. On the other hand, the Middle East and Africa region has witnessed a growth in need for CRRT solutions due to rising awareness about renal diseases and continuously developing healthcare infrastructure adopting new treatment options supported by clinical studies. In Asia-Pacific, China, Japan, and India are major contributors to the CRRT market growth due to factors including a large patient pool with kidney disorders, a growing medical tourism industry, and expanding healthcare infrastructure, coupled with an increasing focus on research initiatives enabling rapid adoption of advanced technologies in this region. As a result, manufacturers remain agile by adapting regulatory compliance measures and participating in strategic collaborations with governments and entities to form footprints in the CRRT market.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Continuous Renal Replacement Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising incidences of acute kidney injury (AKI) and chronic kidney diseases (CKD)
- Availability of improved CCRT systems for pediatric and neonatal patients

Market Restraints
- High cost of continuous renal replacement therapy procedure

Market Opportunities
- Ongoing research and development for enhanced safety and efficacy of CRRT
- Favorable government approvals for CRRT machines and techniques

Market Challenges
- Technical complications associated with continuous renal replacement therapy

Market Segmentation Analysis
- Product: Growing prevalence toward acute kidney injury (AKI) boosting a need for CRRT devices for seamless treatment procedures
- Modality: Utilization of continuous venovenous hemodiafiltration for liberal fluid management in renal therapies
- Age Group: Differing CRRT requirements among pediatric population
- Indication: Growing adoption of non-renal indications in extracorporeal renal therapies
- End User: Increasing uses of CRRT devices in hospitals to cater a patients need

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Continuous Renal Replacement Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Continuous Renal Replacement Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

B. Braun Receives FDA Clearance for AQUAbase nX Reverse Osmosis System

B. Braun Medical Inc. has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AQUAbase nX Reverse Osmosis System. This innovative device offers dialysis patients access to high-quality water without the use of chemicals, boasting an impressive raw water conversion rate of up to 75%. [Published On: 2023-09-18]

Quanta Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies

Quanta Dialysis Technologies, a medical technology company, has announced that its Quanta Dialysis System has received FDA 510(k) approval for an expanded indication. This compact and user-friendly hemodialysis device now offers Continuous Renal Replacement Therapy (CRRT), including Continuous VenoVenous Hemodialysis (CVVHD) and Slow Continuous Ultrafiltration (SCUF). The Quanta Dialysis System stands out as the only dialysis device cleared by the FDA to provide Intermittent Hemodialysis (IHD), Sustained Low-Efficiency Dialysis (SLED), and Bagless CRRT. [Published On: 2023-08-03]

Rockwell Medical Announces 3-Year Co-Promotional Collaboration with B. Braun Medical

Rockwell Medical, Inc., a healthcare company, has entered into a 3-year co-promotion services agreement with B. Braun Medical Inc. As part of the agreement, B. Braun is planned to be compensated for any sales resulting from its promotional efforts. This strategic partnership allows Rockwell Medical to expand its customer base and generate new business leads, ultimately improving the lives of more hemodialysis patients. [Published On: 2023-06-29]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Continuous Renal Replacement Therapy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Continuous Renal Replacement Therapy Market, highlighting leading vendors and their innovative profiles. These include Anjue Medical Equipment Co., Ltd., Asahi Kasei Medical Co., Ltd., B. Braun SE, Baxter International Inc., Biomedica Medizinprodukte GmbH, Braun & Co. Limited, CytoSorbents Corporation, DIAMED Medizintechnik GmbH, Fresenius Medical Care AG & Co. KGaA, Infomed SA, Joline GmbH & Co. KG, Medites Pharma spol. s.r.o, Medtronic PLC, Miromatrix Medical Inc., Nextkidney B.V., Nikkiso Co., Ltd., Ningbo Tianyi Medical Devices Co., Ltd., Nipro Corporation, Nuwellis, Inc., Quanta Dialysis Technologies Limited, SB-KAWASUMI LABORATORIES, INC., Shionogi & Company, Limited, Sphingotec GmbH, SWS Hemodialysis Care Co. Ltd., Thermo Fisher Scientific Inc., and Toray Medical Co., Ltd. by Toray Industries, Inc..

Market Segmentation & Coverage

This research report categorizes the Continuous Renal Replacement Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- CRRT Systems
- Dialysates & Replacement Fluids
- Disposables
  - Bodyline sets & tubes
  - Hemofilters
Modality
- Continuous Venovenous Hemodiafiltration
- Continuous Venovenous Hemodialysis
- Continuous Venovenous Hemofiltration
- Slow Continuous Ultrafiltration

Age Group
- Adults
- Pediatrics

Indication
- Non-renal
- Renal

End User
- Dialysis Clinics
- Homecare
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-433AB1DC293A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidences of acute kidney injury (AKI) and chronic kidney diseases (CKD)
  - 5.1.1.2. Availability of improved CCRT systems for pediatric and neonatal patients
- 5.1.2. Restraints
  - 5.1.2.1. High cost of continuous renal replacement therapy procedure
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research and development for enhanced safety and efficacy of CRRT
  - 5.1.3.2. Favorable government approvals for CRRT machines and techniques
- 5.1.4. Challenges
  - 5.1.4.1. Technical complications associated with continuous renal replacement therapy
5.2. Market Segmentation Analysis
- 5.2.1. Product: Growing prevalence toward acute kidney injury (AKI) boosting a need for CRRT devices for seamless treatment procedures
- 5.2.2. Modality: Utilization of continuous venovenous hemodiafiltration for liberal fluid management in renal therapies
- 5.2.3. Age Group: Differing CRRT requirements among pediatric population
- 5.2.4. Indication: Growing adoption of non-renal indications in extracorporeal renal therapies
- 5.2.5. End User: Increasing uses of CRRT devices in hospitals to cater a patients need
5.3. Market Trend Analysis
- 5.3.1. Established companies in the North America receiving favorable government approvals for CRRT and their potential expansion in the South American market
- 5.3.2. Growing number of renal patients in Asia leads to an increased need for continuous renal replacement therapies
- 5.3.3. Supportive government policies and financial initiatives from established vendors for the kidney health contributed to CRRT advancement across EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Continuous Renal Replacement Therapy Market, by Product

6.1. Introduction
6.2. CRRT Systems
6.3. Dialysates & Replacement Fluids
6.4. Disposables

7. Continuous Renal Replacement Therapy Market, by Modality

7.1. Introduction
7.2. Continuous Venovenous Hemodiafiltration
7.3. Continuous Venovenous Hemodialysis
7.4. Continuous Venovenous Hemofiltration
7.5. Slow Continuous Ultrafiltration

8. Continuous Renal Replacement Therapy Market, by Age Group

8.1. Introduction
8.2. Adults
8.3. Pediatrics

9. Continuous Renal Replacement Therapy Market, by Indication

9.1. Introduction
9.2. Non-renal
9.3. Renal

10. Continuous Renal Replacement Therapy Market, by End User

10.1. Introduction
10.2. Dialysis Clinics
10.3. Homecare
10.4. Hospitals

11. Americas Continuous Renal Replacement Therapy Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Continuous Renal Replacement Therapy Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Continuous Renal Replacement Therapy Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. B. Braun Receives FDA Clearance for AQUAbase nX Reverse Osmosis System
- 14.3.2. Quanta Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies
- 14.3.3. Rockwell Medical Announces 3-Year Co-Promotional Collaboration with B. Braun Medical
- 14.3.4. Nuwellis, DaVita partner on ultrafiltration therapy pilot program
- 14.3.5. Baxter, Miromatrix Partner on Liver Failure Research
- 14.3.6. PBMC Launches New Renal Therapy Option for Dialysis Patients
- 14.3.7. SeaStar Medical, Nuwellis Partner on Kidney Injury Treatment
- 14.3.8. Spectral Medical Announces Strategic Joint Venture with Infomed to Accelerate Commercialization of DIMI and SAMI Dialysis Devices.
- 14.3.9. Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio